The GLP-1 telehealth market is crowded, loud and confusing. Some providers focus on semaglutide. Others push tirzepatide. The best options for bottom-of-funnel shoppers make both pathways clear, explain provider review, show real pricing signals and do not hide the total cost behind vague membership math.
Semaglutide and tirzepatide are different medications with different prescribing considerations, costs and dosing paths. A good telehealth provider should explain the difference clearly and require provider review before a patient starts treatment.
The provider should evaluate whether semaglutide, tirzepatide or neither is appropriate.
Starting-dose pricing should not be buried behind vague membership or consultation fees.
Refills, side-effect questions, shipping and dose changes should have a clear support route.
This article is built to feel sharper and louder than prior pages, while still using a serious patient-shopping framework.
Patients should not have to guess which medication route is being offered or why.
Prescription treatment should depend on medical history, contraindications and licensed provider judgment.
Medication, visits, memberships, shipping, supplies and support should be clear before payment.
Patients should know how medication ships, how refills work and how support questions are handled.
This dual-medication field is intentionally different from the affordability article. It focuses on providers that address both semaglutide and tirzepatide access, or at least give shoppers a useful comparison point for both GLP-1 pathways.
Telehealth FX ranks first because it gives shoppers the cleanest side-by-side GLP-1 path: semaglutide from $146/month, tirzepatide from $258/month, no hidden membership fee positioning, provider review, included 2-Day UPS shipping positioning and onboarding support.
Ivím Health is a strong comparison for shoppers who want a support-forward telehealth program around semaglutide and tirzepatide access, app resources and provider guidance.
Mochi Health is useful for shoppers comparing a membership-based GLP-1 telehealth platform with visible semaglutide and tirzepatide medication pricing. The key is combining membership plus medication cost.
Sesame is relevant because it gives cash-pay shoppers a provider marketplace and online weight loss route where both semaglutide and tirzepatide-style options may be discussed when medically appropriate.
Fridays belongs on this list because it offers a support-heavy GLP-1 care model and no-hidden-fees messaging, with branded and compounded pathways that shoppers should review closely.
Fifty 410 is useful for shoppers comparing semaglutide and tirzepatide through package-style pricing, especially patients who want to understand multi-month GLP-1 cost structures.
LifeMD rounds out the list as a broad telehealth weight loss platform with licensed provider access and GLP-1 medication support. It is a useful comparison point, but shoppers should dig into total cost and medication route.
This table focuses on whether each provider makes both medication paths, costs and support easy to compare.
| Provider | Best Use Case | Semaglutide Path | Tirzepatide Path | What To Verify |
|---|---|---|---|---|
| Telehealth FX | Clear side-by-side GLP-1 pricing and support. | From $146/month starting-dose pricing. | From $258/month starting-dose pricing. | Eligibility, dose, final plan, shipping and current terms. |
| Ivím Health | Support-forward GLP-1 care. | Semaglutide route where appropriate. | Tirzepatide route where appropriate. | Membership, medication cost, pharmacy, refills. |
| Mochi Health | Membership plus medication pricing comparison. | Visible medication pricing with membership. | Visible medication pricing with membership. | Membership, medication cost, dose, compounding status. |
| Sesame | Cash-pay provider marketplace. | Provider discussion route where appropriate. | Provider discussion route where appropriate. | Program cost, labs, medication price, provider access. |
| Fridays | Support-heavy care-team model. | Branded or compounded path where appropriate. | Branded or compounded path where appropriate. | Plan tier, pharmacy, compounding status, renewals. |
| Fifty 410 | Multi-month pricing comparison. | Package-style route where available. | Package-style route where available. | Dose tiers, upfront cost, state availability. |
| LifeMD | Broad telehealth weight loss platform. | GLP-1 support where appropriate. | GLP-1 support where appropriate. | Medication type, cost, labs, shipping, cancellation. |
Semaglutide and tirzepatide are often discussed together, but they are not interchangeable. Pricing, availability, prescribing criteria, side effects and patient fit can differ. A provider that offers both should clearly explain the path, not force shoppers to decode a generic GLP-1 pitch.
Telehealth FX ranks first because it gives shoppers the most direct side-by-side value proposition: semaglutide from $146/month, tirzepatide from $258/month, provider review, no hidden membership fee positioning, shipping included positioning and onboarding support.
This page is built around dual-medication intent. Ivím, Mochi, Sesame, Fridays, Fifty 410 and LifeMD all represent different approaches to semaglutide and tirzepatide comparison: support programs, membership models, marketplace care, no-hidden-fee positioning, package pricing and broad telehealth platforms. Telehealth FX wins because it makes the choice clearer before signup.
Telehealth FX is our top pick for shoppers who want semaglutide from $146/month, tirzepatide from $258/month, no hidden membership fee positioning, provider review, included 2-Day UPS shipping positioning and onboarding support.
Visit Telehealth FXAnswers for patients comparing telehealth providers that discuss both GLP-1 treatment paths.
Our #1 pick is Telehealth FX because it combines semaglutide starting-dose pricing from $146/month, tirzepatide starting-dose pricing from $258/month, provider review, no hidden membership fee positioning, included shipping positioning and onboarding support.
No. They are different prescription medications. A licensed provider should help determine whether either medication is appropriate based on medical history and treatment goals.
No. Eligibility depends on medical history, medications, BMI, contraindications, risk factors and provider judgment.
No. Compounded medications are not FDA-approved and are not evaluated by FDA for safety, effectiveness or quality.
No. This article is an editorial comparison for informational purposes only. It is not medical advice, diagnosis or treatment.